NO20023036L - Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorer - Google Patents
Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorerInfo
- Publication number
- NO20023036L NO20023036L NO20023036A NO20023036A NO20023036L NO 20023036 L NO20023036 L NO 20023036L NO 20023036 A NO20023036 A NO 20023036A NO 20023036 A NO20023036 A NO 20023036A NO 20023036 L NO20023036 L NO 20023036L
- Authority
- NO
- Norway
- Prior art keywords
- protein
- src
- modified
- inhibitors
- yes
- Prior art date
Links
- 230000008728 vascular permeability Effects 0.000 title abstract 5
- 230000033115 angiogenesis Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000009076 src-Family Kinases Human genes 0.000 abstract 3
- 108010087686 src-Family Kinases Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 229940121649 protein inhibitor Drugs 0.000 abstract 2
- 239000012268 protein inhibitor Substances 0.000 abstract 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 abstract 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- WYZWZEOGROVVHK-GTMNPGAYSA-N radicicol Chemical compound C/1=C/C=C/C(=O)CC2=C(Cl)C(O)=CC(O)=C2C(=O)O[C@H](C)C[C@H]2O[C@@H]2\1 WYZWZEOGROVVHK-GTMNPGAYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/470,881 US6685938B1 (en) | 1998-05-29 | 1999-12-22 | Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases |
| US53824800A | 2000-03-29 | 2000-03-29 | |
| PCT/US2000/035396 WO2001045751A1 (en) | 1999-12-22 | 2000-12-22 | Angiogenesis and vascular permeability modulators and inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20023036D0 NO20023036D0 (no) | 2002-06-21 |
| NO20023036L true NO20023036L (no) | 2002-07-22 |
Family
ID=27043259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023036A NO20023036L (no) | 1999-12-22 | 2002-06-21 | Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorer |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1250155B1 (de) |
| JP (1) | JP2003518077A (de) |
| KR (1) | KR100813818B1 (de) |
| CN (1) | CN1434727A (de) |
| AT (2) | ATE392215T1 (de) |
| AU (1) | AU781444B2 (de) |
| BR (1) | BR0016547A (de) |
| CA (1) | CA2395136A1 (de) |
| CZ (1) | CZ304320B6 (de) |
| DE (1) | DE60038631T2 (de) |
| DK (2) | DK1905457T3 (de) |
| ES (2) | ES2383763T3 (de) |
| HU (1) | HU229628B1 (de) |
| NO (1) | NO20023036L (de) |
| PL (1) | PL356815A1 (de) |
| PT (2) | PT1250155E (de) |
| RU (1) | RU2271216C2 (de) |
| SK (1) | SK287575B6 (de) |
| WO (1) | WO2001045751A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030130209A1 (en) | 1999-12-22 | 2003-07-10 | Cheresh David A. | Method of treatment of myocardial infarction |
| ATE328888T1 (de) | 2000-08-25 | 2006-06-15 | Sloan Kettering Inst Cancer | Radicicol und monocillin und ihre analogen und ihre anwendungen |
| JP2006507021A (ja) * | 2002-03-18 | 2006-03-02 | メドトロニック・エイヴイイー・インコーポレーテッド | 再狭窄の危険のある解剖学的部位へ抗増殖性組成物を送付するための医療用具 |
| CN1681525A (zh) * | 2002-07-12 | 2005-10-12 | 曹义海 | 一种抑制血管渗漏和组织水肿的方法 |
| EP1413887A1 (de) * | 2002-10-22 | 2004-04-28 | Aventis Pharma S.A. | Src Kinase Inhibitoren zur Behandlung von Alzheimer Krankheit |
| AU2003295268A1 (en) * | 2002-12-19 | 2004-07-14 | To-Bbb Holding B.V. | Nucleic acids involved in blood-brain barrier control |
| GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| ATE481134T1 (de) * | 2004-01-21 | 2010-10-15 | Univ Emory | Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen |
| US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
| EP1965762A1 (de) * | 2005-12-23 | 2008-09-10 | Alcon, Inc. | Pharmazeutische formulierung zur verabreichung rezeptor-tyrosin-kinase-hemmender verbindungen ins auge |
| BRPI0711901A2 (pt) * | 2006-05-22 | 2012-03-06 | The Regents Of The University Of California | Composições e métodos para a liberação de oxigênio |
| DK1862802T3 (da) * | 2006-06-01 | 2009-04-14 | Cellzome Ag | Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70 |
| DE102007037008B4 (de) * | 2007-08-06 | 2015-09-10 | Siemens Aktiengesellschaft | Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors |
| WO2011053048A2 (ko) * | 2009-10-29 | 2011-05-05 | 연세대학교 산학협력단 | 신규 혈관누출 차단제 |
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| US10293023B2 (en) | 2013-03-15 | 2019-05-21 | Children's Medical Center Corporation | Method of altering vascular permeability and uses thereof |
| CN105288654B (zh) * | 2015-01-23 | 2018-11-30 | 中国人民解放军第二军医大学 | 蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用 |
| CN105311645B (zh) * | 2015-01-23 | 2018-11-30 | 中国人民解放军第二军医大学 | 胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356167A (en) | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
| US5092885A (en) | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
| ATE120860T1 (de) * | 1990-01-26 | 1995-04-15 | Washington Res Found | Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten. |
| EP0470569B1 (de) | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| US5922697A (en) * | 1996-10-02 | 1999-07-13 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins |
| US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
| ATE292623T1 (de) * | 1997-05-07 | 2005-04-15 | Sugen Inc | 2-indolinonderivate als modulatoren der proteinkinase-ativität |
| US6723694B1 (en) * | 1997-05-21 | 2004-04-20 | The Children's Medical Center Corp. | Short peptides which selectively modulate intracellular signalling |
| US6420338B1 (en) * | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| JP2001518502A (ja) * | 1997-10-06 | 2001-10-16 | ビーエーエスエフ アクチェンゲゼルシャフト | チロシンキナーゼ活性を阻害するためのインデノ［１，２−ｃ］ピラゾール誘導体 |
| DK1082415T3 (da) * | 1998-05-29 | 2011-06-14 | Scripps Research Inst | Anvendelige fremgangsmåder til modulation af angioge-nese ved anvendelse af tyrosin kinase SRC |
| CZ20011564A3 (cs) * | 1998-11-06 | 2002-04-17 | Basf Aktiengesellschaft | Léčivo pro inhibici vaskulární hyperpermeability |
-
2000
- 2000-12-22 EP EP00990365A patent/EP1250155B1/de not_active Expired - Lifetime
- 2000-12-22 SK SK849-2002A patent/SK287575B6/sk not_active IP Right Cessation
- 2000-12-22 HU HU0203957A patent/HU229628B1/hu not_active IP Right Cessation
- 2000-12-22 JP JP2001546690A patent/JP2003518077A/ja active Pending
- 2000-12-22 AT AT00990365T patent/ATE392215T1/de active
- 2000-12-22 DE DE60038631T patent/DE60038631T2/de not_active Expired - Lifetime
- 2000-12-22 DK DK07020078.7T patent/DK1905457T3/da active
- 2000-12-22 ES ES07020078T patent/ES2383763T3/es not_active Expired - Lifetime
- 2000-12-22 CA CA002395136A patent/CA2395136A1/en not_active Abandoned
- 2000-12-22 PL PL00356815A patent/PL356815A1/xx not_active Application Discontinuation
- 2000-12-22 AT AT07020078T patent/ATE553782T1/de active
- 2000-12-22 ES ES00990365T patent/ES2303514T3/es not_active Expired - Lifetime
- 2000-12-22 BR BR0016547-6A patent/BR0016547A/pt not_active Application Discontinuation
- 2000-12-22 DK DK00990365T patent/DK1250155T3/da active
- 2000-12-22 KR KR1020027008102A patent/KR100813818B1/ko not_active IP Right Cessation
- 2000-12-22 PT PT00990365T patent/PT1250155E/pt unknown
- 2000-12-22 PT PT07020078T patent/PT1905457E/pt unknown
- 2000-12-22 EP EP07020078A patent/EP1905457B1/de not_active Expired - Lifetime
- 2000-12-22 WO PCT/US2000/035396 patent/WO2001045751A1/en active Application Filing
- 2000-12-22 RU RU2002119399/15A patent/RU2271216C2/ru not_active IP Right Cessation
- 2000-12-22 CZ CZ2002-2156A patent/CZ304320B6/cs not_active IP Right Cessation
- 2000-12-22 AU AU27400/01A patent/AU781444B2/en not_active Ceased
- 2000-12-22 CN CN00819151A patent/CN1434727A/zh active Pending
-
2002
- 2002-06-21 NO NO20023036A patent/NO20023036L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2383763T3 (es) | 2012-06-26 |
| HUP0203957A3 (en) | 2005-07-28 |
| PT1250155E (pt) | 2008-06-06 |
| CZ304320B6 (cs) | 2014-03-05 |
| HUP0203957A2 (hu) | 2003-03-28 |
| ES2303514T3 (es) | 2008-08-16 |
| RU2271216C2 (ru) | 2006-03-10 |
| KR100813818B1 (ko) | 2008-03-17 |
| DE60038631T2 (de) | 2009-06-10 |
| EP1250155A1 (de) | 2002-10-23 |
| DK1905457T3 (da) | 2012-05-29 |
| SK8492002A3 (en) | 2002-11-06 |
| CN1434727A (zh) | 2003-08-06 |
| BR0016547A (pt) | 2002-10-29 |
| RU2002119399A (ru) | 2004-02-27 |
| EP1250155A4 (de) | 2003-08-20 |
| NO20023036D0 (no) | 2002-06-21 |
| ATE553782T1 (de) | 2012-05-15 |
| JP2003518077A (ja) | 2003-06-03 |
| DE60038631D1 (de) | 2008-05-29 |
| AU2740001A (en) | 2001-07-03 |
| AU781444B2 (en) | 2005-05-26 |
| SK287575B6 (sk) | 2011-03-04 |
| PT1905457E (pt) | 2012-05-25 |
| KR20020063259A (ko) | 2002-08-01 |
| WO2001045751A1 (en) | 2001-06-28 |
| CA2395136A1 (en) | 2001-06-28 |
| EP1905457A1 (de) | 2008-04-02 |
| ATE392215T1 (de) | 2008-05-15 |
| EP1250155B1 (de) | 2008-04-16 |
| DK1250155T3 (da) | 2008-08-25 |
| HU229628B1 (en) | 2014-03-28 |
| EP1905457B1 (de) | 2012-04-18 |
| PL356815A1 (en) | 2004-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20023036L (no) | Angiogenese og vaskul¶r permeabilitetsmodulatorer og inhibitorer | |
| ATE469888T1 (de) | Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren | |
| HUS1700003I1 (hu) | Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok | |
| WO2002057259A3 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| DE60105295D1 (de) | Chinazolinderivate zur behandlung von tumoren | |
| CY1108041T1 (el) | Αναστολεις της rho-κινασης | |
| ATE556059T1 (de) | Pyrazolderivate zur behandlung von hiv | |
| WO2002076976A3 (en) | Rho-kinase inhibitors | |
| ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| ATE367160T1 (de) | Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma | |
| NO20000519L (no) | 2-acylaminopropanaminer som takykininreseptorantagonister | |
| NO20006026L (no) | Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC | |
| ATE264309T1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
| NO20002408L (no) | 5-HT1F antagonister | |
| DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen | |
| ATE314070T1 (de) | Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln | |
| DE60311284D1 (de) | 4-(3,5-dicyanophenoxy)pyrazol-derivate zur verwendung als reverse transkriptase modulatoren zur behandlung von u.a. hiv | |
| DE50105650D1 (de) | Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose | |
| DE60104577D1 (de) | Verwendung von mono- und bifunktionalen (Per)Fluoropolyetherderivaten zur Behandlung von keramischen Werkstoffen | |
| ATE344666T1 (de) | Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht | |
| DE60209703D1 (de) | Verwendung eines alpinia officinarum wurzelstöcke extraktes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |